Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Withdrawn 1Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 4CNS 4NET 3Head & Neck 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 15Paraganglioma 4Meningioma 4Carcinoma, Neuroendocrine 4Pheochromocytoma 3Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Medullary 2Carcinoid Tumor 2Somatostatinoma 1Serotonin Syndrome 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Neuroblastoma 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Disease Progression 1Carcinoma, Merkel Cell 1Carcinoid Heart Disease 1Breast Neoplasms 1Advanced Lung Neuroendocrine Tumor 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 4Temozolomide 4anlotinib 3Specimen Handling 3cabozantinib 2belzutifan 2Sunitinib 2Magnetic Resonance Spectroscopy 2Axitinib 23-Iodobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2talazoparib 1pembrolizumab 1pazopanib 1olaparib 1lanreotide 1guadecitabine 1gallium Ga 68 dotatate 1copper dotatate CU-64 1atezolizumab 1ONC206 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Paraganglioma × lutetium Lu 177 dotatate × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT04029428 2020-04-01

POLNETS_PRRT

University of Warmia and Mazury

Phase 2 Unknown
150 enrolled
CNSEndocrineNET

Paraganglioma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡